Table 1.
Mean bladder pressures and urodynamic parameters during open outlet, conscious cystometry in control rats and those exposed to RVS before and after intravesical infusion of a TRPV4 agonist or antagonist
| Group Size | Threshold Pressure, kPa | Micturition Pressure, kPa | Baseline Pressure, kPa | Intercontraction Interval, s | Infused Volume, ml | Void Volume, ml | |
|---|---|---|---|---|---|---|---|
| Control | |||||||
| Pre-DMSO | 6 | 1.4 ± 0.2 | 3.9 ± 0.5 | 1.0 ± 0.1 | 388.6 ± 9.3 | 1.1 ± 0.1 | 1.2 ± 0.1 |
| Post-DMSO | 6 | 1.6 ± 0.2 | 4.8 ± 0.7 | 1.0 ± 0.1 | 494.7 ± 27.9 | 1.4 ± 0.1 | 1.3 ± 0.1 |
| Preagonist | 4 | 1.4 ± 0.1 | 4.0 ± 0.7 | 1.0 ± 0.1 | 386.8 ± 49.8 | 1.1 ± 0.1 | 1.1 ± 0.2 |
| Postagonist | 4 | 1.3 ± 0.1 | 4.8 ± 0.8 | 1.2 ± 0.1 | 104.6 ± 11.4§ | 0.3 ± 0.1§ | 0.3 ± 0.1‡ |
| Preantagonist | 5 | 1.3 ± 0.1 | 3.9 ± 0.3 | 1.1 ± 0.1 | 376.0 ± 33.7 | 1.1 ± 0.1 | 1.1 ± 0.1 |
| Postantagonist | 5 | 1.5 ± 0.1 | 4.2 ± 0.3 | 1.1 ± 0.1 | 502.8 ± 28.5* | 1.4 ± 0.1* | 1.3 ± 0.1 |
| RVS | |||||||
| Pre-DMSO | 4 | 1.0 ± 0.1 | 3.0 ± 0.5 | 0.9 ± 0.1 | 198.2 ± 28.6 | 0.6 ± 0.1 | 0.5 ± 0.1 |
| Post-DMSO | 4 | 1.1 ± 0.1 | 3.5 ± 0.7 | 0.8 ± 0.2 | 267.5 ± 16.3 | 0.7 ± 0.1 | 0.7 ± 0.1 |
| Preagonist | 4 | 1.0 ± 0.1 | 2.7 ± 0.1 | 0.9 ± 0.1 | 113.0 ± 14.6 | 0.3 ± 0.1 | 0.3 ± 0.1 |
| Postagonist | 4 | 1.3 ± 0.1 | 3.7 ± 0.3* | 1.2 ± 0.1 | 85.3 ± 8.4 | 0.2 ± 0.1 | 0.2 ± 0.1 |
| Preantagonist | 6 | 2.0 ± 0.7 | 4.4 ± 0.8 | 2.0 ± 0.6 | 147.7 ± 18.9 | 0.4 ± 0.1 | 0.4 ± 0.1 |
| Postantagonist | 6 | 1.5 ± 0.2 | 4.0 ± 0.6 | 1.3 ± 0.2 | 319.7 ± 19.4‡ | 0.9 ± 0.1‡ | 0.9 ± 0.1† |
Values are means ± SE; n = 4–6/group. Threshold, micturition, and baseline pressures (kPa) during conscious cystometry for control and repeated variate stress (RVS)-treated (7 days) rats are shown. Urodynamic parameters including intercontraction interval (s), infused volume (ml), and void volume (ml) are also shown. For each group (control and RVS), values before and after instillation of 3 pharmacological treatments [vehicle (0.1% DMSO), agonist (GSK1016790A), and antagonist (HC067047)] are presented. TRPV4, transient receptor potential ion channel vanilloid 4. Statistical analyses were performed using repeated-measures ANOVA for vehicle-treated groups and two-way ANOVA with Bonferroni multiple (6) comparisons as described in Statistical Analyses.
P ≤ 0.05;
P ≤ 0.01;
P ≤ 0.001;
P ≤ 0.0001.